Drug Trial Radar · NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Assembly BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.
Conditions
- Chronic Hepatitis D Infection
Interventions
ABI-6250Drug
Once daily tablet dosing for 48 weeks starting at Day 1 visit
ABI-6250Drug
Once daily tablet dosing for 48 weeks, starting at Week 16 visit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results.Time frame: Through study completion, an average of 1.5 years.
- Evaluating the change from baseline in HDV RNA & ALT levelsTime frame: Through study completion, an average of 1.5 years.
Locations
22 sites in 11 countries. Site status is shown where the registry gives one.
AP-HP - Beaujon Hospital
Clichy, France
Hôpital Henri-Mondor
Créteil, France
CHU Lyon - Hôpital Croix-Rousse
Lyon, France
LLC Neolab
Tbilisi, Georgia
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
Azienda Ospedaliera Universitaria
Naples, Italy
Clinical Republican Hospital
Chisinau, Moldova
New Zealand Clinical Research
Auckland, New Zealand
Aga Khan University Hospital
Karachi, Pakistan
Dr. Ziauddin Hospital
Karachi, Pakistan
Arensia Research Clinic
Bucharest, Romania
Dr. Victor Babes Foundation
Bucharest, Romania
Fundeni Clinical Institute
Bucharest, Romania
Prof. Dr. Matei Bals National Institute of Infectious Diseases
Bucharest, Romania
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain
ARENSIA Exploratory Medicine Ivano-Frankivsk
Ivano-Frankivsk, Ukraine
Medical Center of LLC ARENSIA Exploratory Medicine
Kyiv, Ukraine
King's College Hospital London
London, United Kingdom
The Royal London Hospital
London, United Kingdom
North Manchester General Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.